S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
AI Stock Caught Trading Under Secret Name (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:EWTX

Edgewise Therapeutics (EWTX) Stock Price, News & Analysis

$17.28
-0.09 (-0.52%)
(As of 02/23/2024 ET)
Today's Range
$17.27
$18.38
50-Day Range
$7.89
$19.97
52-Week Range
$5.12
$20.69
Volume
467,449 shs
Average Volume
775,290 shs
Market Capitalization
$1.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.00

Edgewise Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
38.9% Upside
$24.00 Price Target
Short Interest
Healthy
11.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.01mentions of Edgewise Therapeutics in the last 14 days
Based on 12 Articles This Week
Insider Trading
Acquiring Shares
$5.10 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.97) to ($1.80) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.80 out of 5 stars

Medical Sector

425th out of 942 stocks

Pharmaceutical Preparations Industry

187th out of 429 stocks


EWTX stock logo

About Edgewise Therapeutics Stock (NASDAQ:EWTX)

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company also develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The Company was incorporated in 2017 and is headquartered in Boulder, Colorado.

EWTX Stock Price History

EWTX Stock News Headlines

AI Stock Caught Trading Under Secret Name
We have uncovered perhaps the most unusual AI stock we've ever seen.It's expected to see massive revenue this year - $215 billion.  The company holds over 29,000 patents in the U.S. It pays an enormous dividend.
Edgewise Therapeutics: Q4 Earnings Insights
Edgewise Therapeutics Non-GAAP EPS of $0.47
Edgewise Therapeutics Inc (EWTX)
CEO of America's biggest bank has stern warning
CEO of America’s biggest bank says, “I’m not sure if the world is prepared” for what he believes is coming next.
EWTX May 2024 30.000 call
Edgewise Therapeutics GAAP EPS of -$0.41
See More Headlines
Receive EWTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edgewise Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
2/24/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EWTX
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$24.00
High Stock Price Target
$25.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+38.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-67,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.48 per share

Miscellaneous

Free Float
43,186,000
Market Cap
$1.10 billion
Optionable
Optionable
Beta
0.16
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Peter A. Thompson FACP (Age 64)
    M.D., Co-Founder & Independent Chairman
    Comp: $73k
  • Dr. Kevin Koch Ph.D. (Age 64)
    President, CEO & Director
    Comp: $913.1k
  • Dr. Badreddin Edris Ph.D. (Age 37)
    Co-Founder & Independent Director
    Comp: $40k
  • Dr. Alan J. Russell Ph.D. (Age 54)
    Co-Founder, Chief Scientific Officer & Director
    Comp: $657.52k
  • Dr. Joanne M. Donovan M.D. (Age 67)
    Ph.D., Chief Medical Officer
    Comp: $695.48k
  • Mr. R. Michael Carruthers (Age 66)
    Chief Financial Officer
    Comp: $386.01k
  • Mr. John R. Moore (Age 60)
    General Counsel
  • Dr. Behrad Derakhshan Ph.D. (Age 44)
    Chief Business Officer
    Comp: $575.53k
  • Dr. Marc Semigran M.D. (Age 67)
    Chief Development Officer














EWTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Edgewise Therapeutics stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Edgewise Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EWTX shares.
View EWTX analyst ratings
or view top-rated stocks.

What is Edgewise Therapeutics' stock price target for 2024?

3 brokerages have issued twelve-month target prices for Edgewise Therapeutics' stock. Their EWTX share price targets range from $23.00 to $25.00. On average, they anticipate the company's stock price to reach $24.00 in the next year. This suggests a possible upside of 38.9% from the stock's current price.
View analysts price targets for EWTX
or view top-rated stocks among Wall Street analysts.

How have EWTX shares performed in 2024?

Edgewise Therapeutics' stock was trading at $10.94 at the beginning of 2024. Since then, EWTX stock has increased by 58.0% and is now trading at $17.28.
View the best growth stocks for 2024 here
.

Are investors shorting Edgewise Therapeutics?

Edgewise Therapeutics saw a decrease in short interest in January. As of January 31st, there was short interest totaling 5,400,000 shares, a decrease of 33.9% from the January 15th total of 8,170,000 shares. Based on an average daily volume of 856,800 shares, the days-to-cover ratio is presently 6.3 days. Approximately 11.5% of the shares of the company are short sold.
View Edgewise Therapeutics' Short Interest
.

When is Edgewise Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our EWTX earnings forecast
.

How were Edgewise Therapeutics' earnings last quarter?

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) released its earnings results on Wednesday, November, 10th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.21) by $0.05.

What ETFs hold Edgewise Therapeutics' stock?

ETFs with the largest weight of Edgewise Therapeutics (NASDAQ:EWTX) stock in their portfolio include Fidelity Disruptive Medicine ETF (FMED) and iShares Neuroscience and Healthcare ETF (IBRN) and

When did Edgewise Therapeutics IPO?

(EWTX) raised $150 million in an initial public offering on Friday, March 26th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, SVB Leerink and Wedbush PacGrow acted as the underwriters for the IPO.

Who are Edgewise Therapeutics' major shareholders?

Edgewise Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Frazier Life Sciences Management L.P. (4.20%), Vanguard Group Inc. (3.35%), Granahan Investment Management LLC (1.69%), Goldman Sachs Group Inc. (1.39%), Barclays PLC (1.23%) and Opaleye Management Inc. (1.10%). Insiders that own company stock include Alan J Russell, Behrad Derakhshan, Holdings A/S Novo, James E Flynn, Joanne M Donovan, John R Moore, Jonathan C Fox, Jonathan D Root, Kevin Koch, Orbimed Advisors Llc, Peter A Thompson and R Michael Carruthers.
View institutional ownership trends
.

How do I buy shares of Edgewise Therapeutics?

Shares of EWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:EWTX) was last updated on 2/24/2024 by MarketBeat.com Staff